ライフサイエンスコーパス: for treating

1 ep brain stimulation (DBS) has shown promise for treating a range of brain disorders and neurological

2 Targeted nanotherapeutic is a novel strategy for treating a variety of diseases and is an emerging te

3 ody-based immunotherapies hold great promise for treating a variety of diseases in humans.

4 ore, PPARdelta agonists are promising agents for treating a variety of metabolic disorders.

5 Beclin1 activity has important implications for treating a variety of pathologies associated with al

6 Nontransplant approaches for treating aCML have otherwise largely relied on adopt

7 have great potential as both biotherapeutics for treating acute organophosphate toxicity and as biore

8 een approved in the United States and Europe for treating adolescents and adults with chronic hepatit

9 /6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast

10 engineered substitute is a promising avenue for treating advanced intervertebral disc disease.

11 ight RHAMM as a candidate therapeutic target for treating advanced prostate cancer.

12 no consistent evidence that SIT is effective for treating AE, but due to the low quality of evidence

13 munotherapy has emerged as a potent approach for treating aggressive cancers, such as non-small-cell

14 tomidine shows to be useful as a rescue drug for treating agitation due to delirium in nonintubated p

15 st that has recently been approved in Europe for treating alcohol dependence.

16 rinking that have potential as novel targets for treating alcohol use disorder.SIGNIFICANCE STATEMENT

17 dered when developing therapeutic strategies for treating ALS.SIGNIFICANCE STATEMENT It is not known

18 potentially more druggable molecular target for treating Alzheimer's disease.

19 sidered one of the most promising approaches for treating Alzheimer's disease.

20 al vasculature may improve current paradigms for treating AML.

21 on in the IC and subiculum, could be targets for treating amygdala-related disorders.

22 Currently, no therapies exist for treating and improving outcomes in patients with sev

23 lation of adaptive immune system may be used for treating and preventing atherosclerosis.

24 VHL is a potential target for treating anemia and ischemic diseases, motivating th

25 ic bioprostheses (vs. mechanical prostheses) for treating aortic valve disease, and this tendency is

26 spond to Ara-C-based therapy and as a target for treating Ara-C-refractory AML.

27 as a potential alternative to electrotherapy for treating arrhythmia, but feasibility studies have be

28 n and reveals miR-34 as a therapeutic target for treating arrhythmogenesis in heart disease.

29 the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily

30 ghting its potential as a therapeutic target for treating autoimmune diseases.

31 ammation, may provide us with new strategies for treating autoimmune diseases.

32 disease and therefore is a promising target for treating autoimmune diseases.

33 argeting B cells may be a promising strategy for treating autoimmune disorders.

34 or clarithromycin, are promising candidates for treating bacterial infections.

35 oids, the sole insecticide class recommended for treating bed nets, threatens the control of major ma

36 in VTA DA neurons could be a useful strategy for treating behavioral symptoms caused by PE.

37 rm the development of bioelectronic implants for treating blindness.

38 We sought to compare 3 strategies for treating blood pressure in China and India: a treat-

39 rials (RCTs) evaluating isoflavone therapies for treating BMD loss at the lumbar spine and femoral ne

40 earch to explore the S100-targeting reagents for treating breast cancer patients.

41 te ratio, 1.22; 95% CI, 1.07-1.37; P = .002) for treating cancer compared with control states.

42 An emerging approach for treating cancer involves programming patient-derived

43 Discovery of first-in-class medicines for treating cancer is limited by concerns with their to

44 ping more effective individualized platforms for treating cancer patients.

45 of chemotherapeutics is currently available for treating cancer, a technique for rapidly identifying

46 the most promising immunotherapeutic targets for treating cancer, autoimmunity, and infectious diseas

47 al states and provide a potential new target for treating cancer.

48 y-recruiting molecules as immunotherapeutics for treating cancer.

49 e both preventive and therapeutic approaches for treating cardiovascular disease.

50 creased usage of cardiovascular drugs (CVDs) for treating cardiovascular diseases, it is important to

51 est that 3-HAA reduction may be a new target for treating cardiovascular diseases.

52 HSPCs and suggest new therapeutic strategies for treating CBL(mut) myeloid malignancies.

53 eloped and evaluated an ASO-dependent method for treating certain molecularly defined diseases associ

54 Optimizing drugs available for treating children living with HIV in LMICs, providin

55 WHO guidelines reserve antibiotics for treating children with dysentery.

56 or 19 (FGF19) may represent a novel approach for treating cholangiopathy and comorbidities.

57 thereby identifying spinal G-CSF as a target for treating chronic abdominal pain.

58 ly lead to the development of new approaches for treating chronic cardiovascular inflammation in a ma

59 vide the most convincing evidence of benefit for treating chronic gastrointestinal pain and painful F

60 irus (HCV) NS3/4A protease and was developed for treating chronic HCV infection.

61 wn that TAF may be a good alternative to TDF for treating chronic hepatitis B.

62 CDKP1 has emerged as a novel target for treating chronic infections and eliminating latent b

63 enefits of plant-based cannabis preparations for treating chronic pain in adults and the harms of can

64 obiome may also serve as therapeutic targets for treating chronic pelvic pain.

65 an adjunct to scaling and root planing (SRP) for treating chronic periodontitis in patients with type

66 eriostin may be a novel therapeutic strategy for treating CKD.

67 s long been proposed as a potential strategy for treating CNS injury and disease; however, applicatio

68 32476, that may have translational potential for treating cocaine addiction.

69 linical use of nicotine and related agonists for treating cognitive deficits, these data suggest that

70 agonists/inverse agonists also may be useful for treating cognitive deficits.

71 s critical for developing optimal strategies for treating cognitive deficits.

72 which may further lead to cell-based therapy for treating corneal endothelial dysfunction.

73 targeted in potential anti-cancer approaches for treating CRC patients.

74 fic intervention modes may be more effective for treating CRF at different points in the cancer treat

75 a inhibition as a novel therapeutic approach for treating CRS2 and AKI.

76 PK, may be an important therapeutic approach for treating CTS.

77 ses are some of the latest options available for treating DED.

78 placement therapies promise exciting avenues for treating degenerative age-related diseases.

79 port the use of SnCs as a therapeutic target for treating degenerative joint disease.

80 f this study was to evaluate a new technique for treating dehiscence buccal bone sites (Class II) wit

81 target in the dorsolateral prefrontal cortex for treating depression with repetitive transcranial mag

82 f protein reabsorption and potential targets for treating diabetic proteinuria.

83 gs affect the immune system has consequences for treating disease and minimizing unwanted side effect

84 of wide-ranging function hold great promise for treating disease, but immune surveillance of these m

85 sent inroads into new therapeutic approaches for treating diseases affecting the CNS.

86 medicine-based therapeutics and theranostics for treating diseases associated with dysfunctional macr

87 suggest MOSPD2 as a potential target protein for treating diseases in which monocyte and neutrophil a

88 ng cellular PAD2 function and sets the stage for treating diseases in which PAD2 activity is dysregul

89 ns, both for the analysis of physiology, and for treating diseases of the peripheral nervous system,

90 romotors from test tubes to living organisms for treating diseases with high efficacy.

91 t pathway may be a useful therapeutic target for treating disorders characterized by excessive repeti

92 (hPSC)-derived neurons is a promising avenue for treating disorders including Parkinson's disease (PD

93 ble to traditional CS-reactivation paradigms for treating disorders that involve multiple CS-US assoc

94 g attention as a possible therapeutic target for treating disorders that stem from traumatic memories

95 duction of autophagy is a promising approach for treating diverse human diseases, including neurodege

96 ent of more efficient therapeutic approaches for treating DMD patients.

97 (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED).

98 iated viral (AAV) vectors hold great promise for treating Duchenne muscular dystrophy (DMD).

99 c ablation and resection is highly effective for treating dysplastic BE and early EAC, whereas esopha

100 tablished, natural-orifice surgical approach for treating esophageal motility disorders.

101 Though DBS is effective for treating ET, the mechanism through which the therape

102 on of Nav1.1 represents a potential strategy for treating excitability disorders of the brain and per

103 protein B (ApoB)-ASO is an FDA approved drug for treating familial hypercholesterolemia.

104 : Which interventions are effective and safe for treating female pattern hair loss (FPHL)?

105 ducted an evidence-based review on their use for treating FGID syndromes.

106 atrix collagens and may be promising targets for treating fibrogenesis.

107 remains unknown, and no effective therapies for treating fulminant pertussis exist.

108 cating that JNK1 may be a therapeutic target for treating fungal infection.

109 is important for developing novel strategies for treating fungal infections.

110 Nucleic acid editing holds promise for treating genetic disease, particularly at the RNA le

111 ated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular

112 ken together, these data suggest a potential for treating haematological cancers harbouring U2AF1 mut

113 og ganciclovir is the current drug of choice for treating HCMV, knowing the provenance of the dNTPs i

114 bitril, a combination drug recently approved for treating heart failure, inhibits stretch-induced hyp

115 as a potential alternative to electrotherapy for treating heart rhythm disorders, but its applicabili

116 veloping novel targeted epigenetic therapies for treating hematological malignancies.

117 ed immunotherapy may be a promising approach for treating hepatic fibrosis.

118 rubicin had a higher efficacy than etoposide for treating hepatocellular carcinoma.

119 e used as an alternative second line therapy for treating HER2 + BC.

120 ng plasma cholesterol, which could be useful for treating high levels of low-density lipoprotein chol

121 ree survival (DFS), the appropriate strategy for treating high-risk patients is unclear.

122 and efficacy of the different anticoagulants for treating HIT.

123 o infection may lead to therapeutic advances for treating HIV-1.

124 e studies suggest that GS-9620 may be useful for treating HIV-infected individuals on suppressive ant

125 thus have a potential of being a novel agent for treating HIV1-gp120-mediated neuroinflammatory disea

126 -1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit

127 new applications and therapeutic approaches for treating human disease.

128 n of gene editing and stem-cell technologies for treating human disease.

129 gnaling pathways and identifying new targets for treating human diseases.

130 an global inhibition, may be more applicable for treating human glaucoma.

131 We identified drug seeds for treating Huntington's disease (HD) by combining in v

132 lesterol biosynthesis inhibitors widely used for treating hypercholesterolemia, is associated with im

133 he kidney may provide a new molecular target for treating hypertension.

134 ood pressure threshold of less than 90 mm Hg for treating hypotension for individuals 10 years and ol

135 hway offers an innovative therapeutic target for treating hypoxic-ischemic human diseases and organ t

136 entified as the lead LANCL2-binding compound for treating IBD.

137 s-localization, and may offer a new strategy for treating imatinib-resistant GISTs.

138 bicyclic boronate compounds, have potential for treating infections caused by this most intractable

139 e, should lead to the discovery of new drugs for treating infections.

140 previously untapped compounds could be used for treating infectious diseases.

141 nherent advantages over catalytic inhibitors for treating inflammatory diseases.

142 ion and to explore its therapeutic potential for treating inflammatory diseases.

143 r treating influenza B virus infections than for treating influenza A virus infections.

144 antiviral drug oseltamivir is less effective for treating influenza B virus infections than for treat

145 Gene augmentation therapy shows promise for treating inherited retinal degenerations; however, r

146 ule-stabilizing drugs have gained popularity for treating injured adult axons, the rationale being th

147 adipocytes as potential therapeutic targets for treating insulin resistance.

148 ntal signals represents a promising strategy for treating intervertebral disc degeneration.

149 for using minocycline as a therapeutic agent for treating ischemic retinal degeneration.

150 e, but there is still no satisfying solution for treating it.

151 PAK and ROCK, are likely anti-cancer targets for treating K-Ras-driven tumours.

152 nfection and suggests a therapeutic strategy for treating lethal hyperinfection.

153 he potential of immune-modulatory approaches for treating lung cancer with aberrant PML degradation.

154 n identified as possible therapeutic targets for treating lung disease.

155 er agent that is in advanced clinical trials for treating lymphoma and myelofibrosis-was prepared by

156 ndrial fission may be a therapeutic approach for treating macrovascular complications in patients wit

157 able aminoglycosides, they would be suitable for treating many cases of multidrug and extensively dru

158 uripotent stem cells offers enormous promise for treating many diseases, including neurodegenerative

159 elivery across the blood-brain barrier (BBB) for treating many neurological disorders.

160 after monthly injection of anti-VEGF agents for treating ME due to CRVO and HRVO.

161 tDCS devices do not have regulatory approval for treating medical disorders, evidence is largely inco

162 nent of HH signaling and an important target for treating medulloblastoma and other cancers driven by

163 Tranexamic acid is a novel drug for treating melasma that is administered both locally a

164 ing Erk5 integrity has therapeutic potential for treating metabolic stress-induced cardiomyopathy.The

165 ctions of CaMKK2 and demonstrate its utility for treating metabolically-related hepatic disease.

166 a novel and therapeutically viable approach for treating metastatic cancers.

167 and represents the major therapeutic target for treating metastatic prostate cancer (mPC).

168 sfer and short range, offering the potential for treating micrometastases while sparing normal tissue

169 otumors, in addition to its established role for treating micrometastatic and minimal disease.

170 (161)Tb might be more appropriate than (90)Y for treating minimal residual disease.

171 T-cell therapies are a promising approach for treating MM, with a mechanism of action different th

172 ngineered NTIMPs have potential applications for treating MMP-related diseases, including cancer and

173 Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain.

174 um tolerated dose (MTD) remains the backbone for treating most cancers.

175 the success of deep brain stimulation (DBS) for treating movement disorders, there is growing intere

176 size the therapeutic potential of IFN-lambda for treating mucosal viral infections.

177 A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was

178 gic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous disea

179 d inflammation as a novel therapeutic avenue for treating muscle loss in dysferlinopathy.

180 etabolism are attractive therapeutic targets for treating mutant GBA-associated PD.

181 s highlight the promise of bariatric surgery for treating NASH and underscore the need for clinical t

182 gamma (MSDC-0602) would retain its efficacy for treating NASH in a rodent model.

183 R agonists are attractive therapeutic agents for treating neurodegenerative diseases as well as addic

184 n of original multitarget therapeutic agents for treating neurodegenerative diseases, based on conjug

185 disorders, making HDACs therapeutic targets for treating neurodegenerative diseases.

186 of discovering novel therapeutic strategies for treating neurological disorders.

187 er describes a practical consensus guideline for treating neurologists, based on current evidence, fo

188 receptor populations, but hold great promise for treating numerous CNS disorders.

189 We identify a target for treating obesity and type 2 diabetes, the consumptio

190 se tissue, and potential therapeutic targets for treating obesity, diabetes and their associated meta

191 5-HT2A agonist activities, which is approved for treating obesity.

192 onsequence of interventional procedures used for treating obstructive vascular disease.

193 ventional outflow pathway and a novel target for treating ocular hypertension.

194 eration THV is clinically safe and effective for treating older patients with severe AS at increased

195 dy presents and discusses the utility of aFP for treating oncological indications.

196 ur data suggest that ibudilast may be useful for treating opioid use disorders and it may enhance the

197 could afford novel therapeutic opportunities for treating or halting AD.

198 there is no effective pharmacologic approach for treating or preventing AKI.

199 may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotem

200 hogenic mechanisms could lead to new targets for treating or reducing the severity of pancreatitis.

201 ausing gene and can be explored as an option for treating other diseases.

202 Somatic gene therapy is a promising approach for treating otherwise terminal or debilitating diseases

203 Statistical methods are implemented for treating outliers, benchmarking sampling adequacy, c

204 benefits of topical corticosteroid therapy, for treating pain and discomfort, are not associated wit

205 noid-based therapies may be more appropriate for treating pain disorders in which hyperalgesia and no

206 Opiates are essential for treating pain, but termination of opiate therapy can

207 ing making it a potential therapeutic target for treating pain.

208 d lacrimal mucosal flap technique in EES-DCR for treating PANDO is simple and safe, can effectively c

209 ut-brain axis could lead to novel approaches for treating particular neurological conditions.

210 pathy, and searching for potential therapies for treating pathologic hyperbilirubinemia.

211 on protein paxillin is an effective strategy for treating pathologic retinal neovascularization.

212 d the resolution of inflammation is critical for treating pathologic wound healing.

213 otential target for modulating SAN rate, and for treating patients affected by SAN dysfunction, parti

214 comparing different pharmacological regimens for treating patients diagnosed as H.pylori infected and

215 We present guidelines for treating patients experiencing CRS and other adverse

216 strate that GRL-09510 has favorable features for treating patients infected with wild-type and/or mul

217 Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carci

218 ent (TAVR) has become a well-accepted option for treating patients with aortic stenosis at intermedia

219 ate that corticosteroids are a powerful tool for treating patients with IgAN; however, treatment succ

220 he way for the development of new strategies for treating patients with melanomas harboring mutant BR

221 ti-platelet therapy represents standard care for treating patients with ST-segment elevation myocardi

222 e products, AgNP topical therapy is proposed for treating patients with upper airway bacterial rhinos

223 They provide a rationale for treating PCa with inhibitors of FGF signaling.

224 on channel as a potential therapeutic target for treating PD.

225 ER stress in vivo and might prove effective for treating PD.

226 picutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only i

227 ation, such as pH changes, may be beneficial for treating periodontitis.

228 NS function and in developing new strategies for treating peripheral neuropathy by targeting SC funct

229 (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumat

230 poptosis is a potential therapeutic approach for treating persistent inflammation, yet neutrophils ha

231 Evidence-based recommendations for treating persons having presumed latent tuberculosis

232 These results are promising for treating PFOA-contaminated water and demonstrate the

233 nts for SJS/TEN, which is of great relevance for treating physicians.

234 ning the efficacy of this front-line regimen for treating Plasmodium falciparum parasites.

235 epressants, has been thought to be effective for treating post-stroke depression (PSD).

236 nabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in man

237 New possibilities for treating posttraumatic stress disorder and anxiety d

238 idea that its potential therapeutic effects for treating posttraumatic stress disorder are related t

239 ine) associated with differences in efficacy for treating prescription opioid dependence, and is long

240 The recovered coagulant was then reused for treating primary wastewater and overall coagulation

241 ow is regarded as a new therapeutic strategy for treating proteolysis-driven chronic inflammatory dis

242 rocessing, which makes it a promising target for treating psychiatric and neurological disease.

243 logical agents currently under investigation for treating psychiatric disorders.

244 le to modifications, is a promising approach for treating PTSD patients.

245 cals, Boston, MA), as a therapeutic strategy for treating pulmonary edema.

246 st as an effective and renewable alternative for treating recalcitrant organic micropollutants.

247 e microbiota and suggest a possible strategy for treating renal disease.

248 A novel therapeutic approach for treating resistant hypertension could be the use of

249 the potential to be effective topical agents for treating respiratory inflammatory diseases.

250 A and IkappaB pathway, which may be targeted for treating S. aureus infection.

251 erapeutic selectivity, and enhanced efficacy for treating schizophrenia and related disorders than cu

252 ein describe their preclinical effectiveness for treating schizophrenia-like behaviors.

253 so point toward novel therapeutic strategies for treating sensory disorders.

254 demonstrate a novel therapeutic opportunity for treating sepsis-induced lymphopenia in humans.

255 ogenitor cell physiology and their potential for treating severe cases of tear deficiency.

256 containing undifferentiated cells are useful for treating skin burns and have potential for regenerat

257 or the utility of the biodegradable nanogels for treating skin cancers.

258 The efficacy and safety of robed-siRNA for treating skin disease was confirmed by its ability t

259 indings support ASOs as a promising approach for treating some human neurodegenerative diseases.

260 results highlights a potential new strategy for treating some myeloid disorders.

261 of this isozyme and may ultimately be useful for treating specific diseases in which PAD2 activity is

262 nd may provide potential therapeutic targets for treating SRS and other polyamine-associated neurolog

263 dynamics is a potential therapeutic approach for treating stress-induced behavioral disorders, and th

264 Evidence-based pharmacological therapies for treating substance use disorders, such as opioid ago

265 Adenosine, the standard therapy for treating supraventricular tachycardia in children an

266 Hydroxychloroquine used for treating systemic lupus erythematosus and a Syk inhi

267 Additional targets are considered for treating tardive dyskinesia and negative and cogniti

268 ollow fiber membranes display huge potential for treating textile wastewater and other impaired efflu

269 SMAD4 axis as a potential therapeutic target for treating TH17-related diseases.

270 al stem cells (hMSCs) is an emerging therapy for treating the failing heart.

271 n a rodent model, indicating their potential for treating the harmful effects of BoNT/A intoxication.

272 (ii) A method is also given for treating the long binding events in the experiments

273 s on the cells and tissues holds the promise for treating the malignant tissue growth, regenerating o

274 that a selected polypharmacological approach for treating the prostanoid-mediated component of inflam

275 that palliative care would have been helpful for treating their symptoms (P < .001).

276 represents a promising therapeutic strategy for treating these disorders, highlighting the need to s

277 may serve as a potential therapeutic target for treating these fear- and anxiety-based disorders in

278 ion has been proposed as a valuable strategy for treating these two important gastrointestinal tract

279 r deciding which proteasome inhibitor to use for treating this disease.

280 BBB may offer new therapeutic opportunities for treating this disorder.

281 us solvation theory (IST) has become popular for treating this effect, but it has not been tested in

282 that these neurons may be a cellular target for treating this form of neuropathic pain.

283 d with a 26% increased rate of thyroidectomy for treating thyroid cancer.

284 The current drug regimens for treating tuberculosis are lengthy and onerous, and h

285 Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients w

286 sed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibitio

287 ascular safety of new antidiabetes therapies for treating type 2 diabetes in 2008, the results of two

288 iting SIRT6 has been proposed as an approach for treating type 2 diabetes mellitus (T2DM).

289 in the kidneys is a relatively new strategy for treating type 2 diabetes.

290 and could be a potential therapeutic target for treating UM in the clinic.

291 T cells has emerged as a promising approach for treating various cancers and chronic infections.

292 , and today is used as an alternative method for treating various diseases and symptoms.

293 medicine therapy that has been found useful for treating various diseases.

294 ter trauma and may provide druggable targets for treating victims of acute nervous system injury.

295 ceptual tasks and therefore has applications for treating visual deficits.

296 therapy has emerged as an important modality for treating vitreous seeding in retinoblastoma.

297 es suggest that 6j could be a promising lead for treating VL as an adjunct therapy with miltefosine.

298 g adaptation, and have clinical implications for treating walking impairments after neurological inju

299 oof of concept for a mixed modality approach for treating X-linked disorders in females.

300 mouse models in identifying drug candidates for treating ZIKV infection and related neurological com